查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511835

美國表觀遺傳學市場規模、佔有率、趨勢分析報告：按產品、按技術、按應用、按最終用途、細分市場預測，2024-2030 年

U.S. Epigenetics Market Size, Share & Trends Analysis Report By Product (Reagents, Kits), By Technology (DNA Methylation, Histone Methylation), By Application (Oncology, Non-oncology), By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國表觀遺傳學市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，美國表觀遺傳學市場規模預計將達到131億美元，2024年至2030年複合年成長率為14.5%。

癌症和慢性病盛行率的增加、表觀遺傳學研究和技術的進步、生物醫學研究投資的增加以及個人化醫療的日益採用將增加預測期內對錶觀遺傳學的需求。

COVID-19 大流行對市場產生了積極影響。這場大流行促使有關了解該病毒及其對人體影響的研究活動顯著增加。其中包括研究 COVID-19 如何影響基因表現和免疫反應的表觀遺傳學研究。因此，政府和私營部門對與 COVID-19 相關的表觀遺傳學研究的資助增加。

此外，企業也增加了對錶觀遺傳產品開發的投資。許多生物技術和製藥公司增加了研發預算，以探索表觀遺傳學在疾病機制和治療反應中的作用。資本的湧入正在加快該領域發現和創新的步伐。衛生系統從外部資金轉向國內投資的轉變凸顯了對創新解決方案的需求。預計表觀遺傳學與醫療保健進步相結合將透過提供改善健康結果的解決方案來改變遊戲規則。

然而，市場成長因缺乏熟練的專業人員而受到限制。表觀遺傳學的複雜性需要對遺傳學、分子生物學和資料分析的深入理解。這種短缺可能會減緩研究和技術進步，阻礙對見解至關重要的複雜資料分析，延遲臨床轉化，並阻礙教育舉措。預計這將在一定程度上阻礙市場成長。

美國表觀遺傳學市場報告亮點

  • 試劑在產品領域佔據主導地位，2023 年收益佔有率最大，為 32.5%。試劑用途廣泛，應用廣泛，包括基礎研究、臨床診斷及藥物開發。同時，服務預計在預測期內將以最快的複合年成長率成長。
  • 在技​​術領域，DNA甲基化在2023年佔據最大的市場佔有率。 DNA甲基化是重要的表觀遺傳修飾之一，在基因表現調控中扮演重要角色。但另一方面，組蛋白乙醯化預計在預測期內以最快的複合年成長率成長。
  • 從應用來看，腫瘤學在 2023 年佔據最大的市場佔有率。這是由於癌症盛行率不斷增加。然而，另一方面，非腫瘤學預計在預測期內將以最快的複合年成長率成長。
  • 根據最終用途，學術研究在 2023 年收益佔有率最大的領域佔據主導地位。這是由於學術機構進行的臨床研究數量不斷增加以及研究活動的資金不斷增加。另一方面，臨床研究預計在預測期內將以最快的複合年成長率成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章美國表觀遺傳學市場：產品業務分析

  • 細分儀表板
  • 美國表觀遺傳學市場：產品變異分析
  • 2018-2030 年美國表觀遺傳學市場規模與趨勢分析（按產品）
  • 試劑
  • 套件
  • 裝置
  • 酵素
  • 服務

第5章美國表觀遺傳學市場：技術商業分析

  • 細分儀表板
  • 美國表觀遺傳學市場：技術波動分析
  • 2018-2030年美國表觀遺傳學合成市場規模及趨勢分析（依技術）
  • DNA甲基化
  • 組蛋白甲基化
  • 組蛋白乙醯化
  • 大非編碼RNA
  • 微型RNA修飾
  • 染色質結構

第6章美國表觀遺傳學市場：應用商業分析

  • 細分儀表板
  • 美國表觀遺傳學市場：應用變異分析
  • 2018-2030 年美國表觀遺傳學合成市場規模與趨勢分析（按應用）
  • 腫瘤學
  • 非腫瘤學

第7章美國表觀遺傳學市場：最終用途業務分析

  • 細分儀表板
  • 美國表觀遺傳學市場：最終用途變異分析
  • 2018-2030 年美國表觀遺傳學市場規模與趨勢分析（依最終用途）
  • 學術研究
  • 臨床調查
  • 醫院/診所
  • 製藥和生物技術公司
  • 其他

第8章 競爭格局

  • 參與企業
  • 策略規劃
  • 2023 年企業市場分析
  • 參與企業概況
    • Roche Diagnostics
    • Thermo Fisher Scientific, Inc.
    • Danaher
    • Eisai Co. Ltd.
    • Novartis AG
    • Element Biosciences, Inc.
    • Dovetail Genomics LLC.
    • Illumina, Inc.
    • Promega Corporation.
    • Abcam plc.
Product Code: GVR-4-68040-301-9

U.S. Epigenetics Market Growth & Trends:

The U.S. epigenetics market size is anticipated to reach USD 13.10 billion by 2030, growing at a CAGR of 14.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of cancer and chronic diseases, advancements in epigenetic research and technologies, rising investment in biomedical research, and increasing adoption of personalized medicine are anticipated to increase the demand for epigenetics over the forecast period.

The COVID-19 pandemic has had a positive impact on the market. The pandemic spurred a significant increase in research activities related to understanding the virus and its effects on human health. This included epigenetic research to study how COVID-19 affects gene expression and immune responses. Consequently, there was increased funding from both government and private sectors for epigenetic studies related to COVID-19.

Moreover, companies have increased investments in the development of epigenetics products. Many biotechnology and pharmaceutical companies have increased their research and development budgets to explore the role of epigenetics in disease mechanisms and treatment responses. This influx of funding has accelerated the pace of discoveries and innovations in the field. The transition from external funding to domestic investment in health systems underscores the need for innovative solutions. Epigenetics, embedded in advancing healthcare, is projected to transform the phase by offering solutions for improving health outcomes.

However, the growth of the market is constrained by a scarcity of skilled professionals. The complex nature of epigenetics demands a deep understanding of genetics, molecular biology, and data analysis. This shortage can decelerate research & technological progress, hinder complex data analysis crucial for insights, slow clinical translation, and hamper educational initiatives. This is anticipated to hamper the growth of the market to a certain extent.

U.S. Epigenetics Market Report Highlights:

  • Reagents dominated the product segment with the largest revenue share of 32.5% in 2023. Reagents are versatile and used in a wide range of applications, including basic research, clinical diagnostics, and drug development. On the other hand, services are expected to grow at the fastest CAGR over the forecast period.
  • The DNA methylation held the largest market share in 2023 for the technology segment. DNA methylation is one of the key epigenetic modifications that plays a vital role in regulating gene expression. However, on the other hand, histone acetylation is expected to grow at the fastest CAGR over the forecast period.
  • The oncology held the largest market share in 2023 for the application segment. This is attributed to the growing prevalence of cancer. However, on the other hand, non-oncology is expected to grow at the fastest CAGR over the forecast period.
  • Based on end-use, academic research dominated the segment with the largest revenue share in 2023. This is attributed to the increasing number of clinical studies which are being conducted in academic institutes and the growing funding for research activities. On the other hand, clinical research is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. End-use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Rising geriatric patient population
      • 3.2.1.3. Increasing government initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of standardization in epigenetics-based diagnostics
      • 3.2.2.2. Lack of skilled professionals
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Epigenetics Market: Product Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Epigenetics Market Product Movement Analysis
  • 4.3. U.S. Epigenetics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Reagents
    • 4.4.1. Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5. Kits
    • 4.5.1. Kits market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.2. ChIP Sequencing Kit
      • 4.5.2.1. ChIP sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.3. Whole Genomic Amplification Kit
      • 4.5.3.1. Whole genomic amplification kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.4. Bisulfite Conversion Kit
      • 4.5.4.1. Bisulfite conversion kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.5. RNA Sequencing Kit
      • 4.5.5.1. RNA sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.6. Others
      • 4.5.6.1. Others market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.6. Instruments
    • 4.6.1. Instruments market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.7. Enzymes
    • 4.7.1. Enzymes market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.8. Services
    • 4.8.1. Services market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Epigenetics Market: Technology Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Epigenetics Market Technology Movement Analysis
  • 5.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 5.4. DNA Methylation
    • 5.4.1. DNA methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. Histone Methylation
    • 5.5.1. Histone methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Histone Acetylation
    • 5.6.1. Histone acetylation market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7. Large Non - coding RNA
    • 5.7.1. Large non - coding RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.8. MicroRNA Modification
    • 5.8.1. MicroRNA modification market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.9. Chromatin Structures
    • 5.9.1. Chromatin structures market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Epigenetics Market: Application Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Epigenetics Market Application Movement Analysis
  • 6.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.2. Solid Tumors
      • 6.4.2.1. Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.3. Liquid Tumors
      • 6.4.3.1. Liquid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5. Non-oncology
    • 6.5.1. Non-oncology market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.2. Inflammatory Diseases
      • 6.5.2.1. Inflammatory diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.3. Metabolic Diseases
      • 6.5.3.1. Metabolic diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.4. Infectious Diseases
      • 6.5.4.1. Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.5. Cardiovascular Diseases
      • 6.5.5.1. Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.6. Others
      • 6.5.6.1. Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. U.S. Epigenetics Market: End-use Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Epigenetics Market End-use Movement Analysis
  • 7.3. U.S. Epigenetics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 7.4. Academic Research
    • 7.4.1. Academic research market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Clinical Research
    • 7.5.1. Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6. Hospitals & Clinics
    • 7.6.1. Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7. Pharmaceutical & Biotechnology Companies
    • 7.7.1. Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8. Others
    • 7.8.1. Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Participant's Overview
    • 8.4.1. Roche Diagnostics
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product & service benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Thermo Fisher Scientific, Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product & service benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Danaher
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product & service benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Eisai Co. Ltd.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product & service benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Novartis AG
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product & service benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Element Biosciences, Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product & service benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Dovetail Genomics LLC.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product & service benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Illumina, Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product & service benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Promega Corporation.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product & service benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Abcam plc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product & service benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. epigenetics market, by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. epigenetics market, by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S. epigenetics market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. epigenetics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Participant's overview
  • Table 8 Financial performance
  • Table 9 Key companies undergoing expansions
  • Table 10 Key companies undergoing acquisitions
  • Table 11 Key companies undergoing collaborations
  • Table 12 Key companies launching new products/services
  • Table 13 Key companies undertaking other strategies

List of Figures

  • Fig. 1 U.S. epigenetics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 U.S. epigenetics market driver analysis
  • Fig. 14 U.S. epigenetics market restraint analysis
  • Fig. 15 U.S. epigenetics market: Porter's analysis
  • Fig. 16 U.S. epigenetics market: Product outlook key takeaways
  • Fig. 17 U.S. epigenetics market: Product movement analysis
  • Fig. 18 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Kits market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 ChIP sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Whole genomic amplification kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Bisulfite conversion kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 RNA sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. epigenetics market: Technology movement analysis
  • Fig. 26 U.S. epigenetics market: Technology outlook and key takeaways
  • Fig. 27 DNA methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Histone methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Histone acetylation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Large non - coding RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 MicroRNA modification market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Chromatin structures market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. epigenetics market: Application movement analysis
  • Fig. 34 U.S. epigenetics market: Application outlook and key takeaways
  • Fig. 35 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Liquid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Non-oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Inflammatory diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Metabolic diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. epigenetics market End-use outlook key takeaways
  • Fig. 45 U.S. epigenetics market: End-use movement analysis
  • Fig. 46 Academic research market estimates and forecast, 2018 - 2030 (USD Million))
  • Fig. 47 Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Key company categorization
  • Fig. 52 Company market positioning
  • Fig. 53 Market participant categorization
  • Fig. 54 Strategy framework